Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors

Continuing to Enroll Patients in Phase 3 LEVEL Study with 52 Investigative Sites Now Initiated